EDUCATION & ACADEMIC TITLES
May 2000: Degree in Medicine by the Medical School of Justus-Liebig University in Giessen, Germany
March 2010: Board certification in Hematology
December 2014: Dissertation by the Medical School of National and Capodistrian University of Athens, Greece: Study of the prognostic impact of serum free light chain ratio in patients with multiple myeloma. Investigation of biological mechanisms regulating secretion of free light chains by neoplasmatic plasma cells
PROFESSIONAL EXPERIENCE
- 7/2000 – 1/2002 Residency in Internal Medicine Klinikum Offenbach, Germany
- 3/2004 – 3/2005 Obligatory Service as General Practicioner
- 5/2005 – 11/2005 Residency in Internal Medicine in the Hospital for special diseases in Thessaloniki, Greece
- 11/2005 – 11/2009 Fellowship in Hematology in “Metaxa” hospital in Piraeus
- 7/2010 – 2/2011 Hematologist, Tzaneio Hospital, Piraeus, Greece
- 2/2011 – 12/2014 Hematologist, Florina General hospital, Greece
- 1/2015 – 5/2015 Hematologist in the clinic for Hematology and Oncology of Marienhospital, Düsseldorf, Germany
- 10/2015 – 5/2018 Hematologist, 1st Propedeutic Clinic for Internal Medicine, Laikon General Hospital, Athens, Greece
- 6/2018 – 7/2022 Hematologist in “Metaxa” hospital in Piraeus
- Since 8/2022 Hematologist in Metropolitan Hospital
MEMBERSHIP IN SOCIETIES & EDITORIAL BOARDS
- Member of Medical Association of Piraeus
- Member of Hellenic Hematology Association
- Member of European Hematology Association
- Reviewer for the scientific Magazine “Case reports in Hematology”
RESEARCH PROGRAMS
- Subinvestigator in MiraCLLe Study: An Epidemiological, Prospective, two-year cohort study to Record the True First- and Second-Line Treatment Strategy, in Daily Clinical Practice, Metropolitan Hospital
DISTINCTIONS & AWARDS
- “Young Investigator Award” for the following oral presentation in the Sixth International Workshop on Waldenstrom’s Macroglobulinemia, October 6 – 10 2010, Venice, Italy.
Clinical impact of increased serum free light chains (sFLCs) or their ratio (FLCR) on WM at diagnosis and during disease course.
D. Maltezas, T. Tzenou, N. Kafassi, E. Koulieris, V. Bartzis, M. Dimou, A. Efthymiou, G. Georgiou, T.P. Vassilakopoulos, M.K. Angelopoulou, P. Tsaftaridis, P. Panayiotidis, P. Beris, M-C Kyrtsonis.
Quantification of serum IgM kappa and IgM lambda in patients with Waldenstrom’s Macroglobulinemia.
E. Koulieris, M-C Kyrtsonis, D. Maltezas, T. Tzenou, L. Mirbahai, G. Mead, P. Panayiotidis, A.R. Bradwell, S. Harding. - Award for best Poster in its category. 7TH International Symposium on Clinical Applications of FLC & HLC, Edinburgh, UK, 16-17/6/15 για την εργασία:
Serum free light chain (FLC) and soluble syndecan-1 levels are major markers of disease evolution of smoldering multiple myeloma (SMM) patients.
Nikolaou E, Maltezas D, Koulieris E, Iliakis T, Viniou NA, Kotsanti S, Bitsani A, Bartzis V, Tzenou T, Dimou M, Panayiotidis P, Kyrtsonis MC.
Hematology Reports 2015; 7(s1), pp28
PUBLICATIONS
- Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, P, Delimpasi S, Michalis E, Anargyrou K,Gavriatopoulou M, Stefanoudaki A, Tzenou T, Koulieris E, Sachanas S, Dimou M, Vassilakopoulos TP, Angelopoulou MK, Pangalis GA, MC. Hematol Oncol. 2012 - Prognostic significance of serum free light chains in Chronic Lymphocytic Leukemia
K. Sarris, D. Maltezas, E. Koulieris, V. Bartzis, T. Tzenou, S. Sachanas, E. Nikolaou, A. Efthymiou, K. Bitsani, M. Dimou, T. Vassilakopoulos, M. Siakantaris, M. Angelopoulou, F. Kontopidou, P. Tsaftaridis, N. Kafasi, G. Pangalis, P. Panayiotidis, S. Harding, M-C. Kyrtsonis.
Adv Hematol. 2013;2013:359071 - Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders.
Kyrtsonis MC, Maltezas D, Koulieris E, Tzenou T, Harding SJ.
WorldJHematol 2013; 2(2): 6-12 - The contribution of prognostic factors to the better management of multiple myeloma patients.
M-C Kyrtsonis, D Maltezas, E Koulieris, Catherine Bitsanis, Ilias Pessach, Anna Efthymiou, Vassiliki Bartzis, Tatiana Tzenou, Panayiotis Panayiotidis.
Multiple Myeloma An Overview Chapter 8: Pages 145-174 - Response to bortezomib in refractory/relapsed multiple myeloma patients: a single center experience with discussion on specific issues.
M-C. Kyrtsonis, D. Maltezas, E. Koulieris, C. Zaroulis, T. Tzenou, S. Sachanas, V. Bartzis, G. Georgiou, M. Dimou, S. Siakavellas, T.P. Vassilakopoulos, M.K. Angelopoulou, E. Koutra, A. Mouzaki, G.A. Pangalis, P. Panayiotidis.
The Asia-Pacific Journal of Oncology & Hematology 2010; Vol 1, Issue 4 - Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
M-C. Kyrtsonis, D. Maltezas, T. Tzenou, E. Koulieris, A.R. Bradwell.
Seminars in Hematology. 2009 (2):110-7 - Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course.
Nikolaou E, Koulieris E, Maltezas D, Sarris A, Iliakis T, Vyniou N.A, Vardounioti I, Κarali V, Pessah I, Efthymiou A, Bitsani A, Bartzis V, Tzenou T, Dimou M, Vassilakopoulos TP, Angelopoulou ΜΚ, Tsaftaridis P, Tsalimalma K, Κafasi Ν, Panayiotidis P, Kyrtsonis M-C.
CurrentCancerTherapyReviews, 2014, 10.2: 90-96 - Biology and treatment of skeletal manifestations in multiple myeloma
Stavropoulos N, Papadoyiannis A, Maltezas D, Stavrou P, Pangalis GA, Papagelopoulos PJ, Kyrtsonis MC.
Journal of Cancer Therapy, 2014, 5, 387-402. - Prognostic contribution of new immunoglobulin biomarkers (Freelite, Hevylite) in Waldenstrom’s Macroglobulinemia (WM).
MC Kyrtsonis, E. Koulieris, D. Maltezas, T. Tzenou, S. Harding, E. Kastritis, N. Kafassi, V. Bartzi, A. Efthymiou, K. Bitsanis, M. Gavriatopoulou, E. Terpos, C. Kalpadakis, M K Angelopoulou, T. P. Vassilakopoulos, AR Bradwell, PH. Berris, GA Pangalis, P. Panayiotidis, MA Dimopoulos
American Journal of Medicine and Medical Science 2012; 2(6): 136-143 - Novel m-component based biomarkers in Waldenström’s Macroglobulinemia.
Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM Clin Lymphoma Myeloma Leuk. 2011;11(1):164-7
